Tirdzniecība Pfizer Inc - PFE CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.05 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.006402% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.005927% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Pfizer Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 43.75 |
| Atvērt* | 43.75 |
| Izmaiņas par 1 gadu* | -18.3% |
| Dienas Diapazons* | 43.32 - 44.02 |
| 52 ned Diapazons | 41.45-56.32 |
| Vidējais apjoms (10 dienas) | 27.76M |
| Vidējais apjoms (3 mēneši) | 448.45M |
| Tirgus Kapitalizācija | 245.64B |
| Cenas/Peļņas Attiecība | 7.99 |
| Izvietotās Akcijas | 5.61B |
| Ieņēmumi | 100.33B |
| EPS | 5.47 |
| Dividende (Ienesīgums %) | 3.74771 |
| Beta | 0.61 |
| Nākamās Peļņas Datums | May 1, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 43.55 | 0.00 | 0.00% | 43.55 | 43.55 | 43.55 |
| Feb 7, 2023 | 43.52 | -0.40 | -0.91% | 43.92 | 44.03 | 43.23 |
| Feb 6, 2023 | 43.75 | -0.13 | -0.30% | 43.88 | 44.28 | 43.56 |
| Feb 3, 2023 | 44.02 | -0.25 | -0.56% | 44.27 | 44.40 | 43.83 |
| Feb 2, 2023 | 44.26 | 0.25 | 0.57% | 44.01 | 44.44 | 43.47 |
| Feb 1, 2023 | 44.01 | -0.20 | -0.45% | 44.21 | 44.24 | 43.39 |
| Jan 31, 2023 | 44.21 | 0.72 | 1.66% | 43.49 | 44.25 | 41.79 |
| Jan 30, 2023 | 43.49 | -0.11 | -0.25% | 43.60 | 44.11 | 43.29 |
| Jan 27, 2023 | 43.71 | -0.43 | -0.97% | 44.14 | 44.32 | 43.45 |
| Jan 26, 2023 | 44.14 | -1.00 | -2.22% | 45.14 | 45.19 | 43.60 |
| Jan 25, 2023 | 45.01 | 0.31 | 0.69% | 44.70 | 45.15 | 44.49 |
| Jan 24, 2023 | 44.71 | -0.26 | -0.58% | 44.97 | 45.01 | 43.99 |
| Jan 23, 2023 | 44.97 | -0.11 | -0.24% | 45.08 | 45.29 | 44.57 |
| Jan 20, 2023 | 44.99 | 0.00 | 0.00% | 44.99 | 45.41 | 44.70 |
| Jan 19, 2023 | 44.98 | 0.00 | 0.00% | 44.98 | 45.24 | 44.52 |
| Jan 18, 2023 | 45.04 | -1.00 | -2.17% | 46.04 | 46.28 | 44.92 |
| Jan 17, 2023 | 46.04 | -1.07 | -2.27% | 47.11 | 47.29 | 45.70 |
| Jan 13, 2023 | 47.72 | 0.10 | 0.21% | 47.62 | 48.13 | 46.99 |
| Jan 12, 2023 | 47.62 | 0.26 | 0.55% | 47.36 | 47.71 | 46.56 |
| Jan 11, 2023 | 47.36 | -0.28 | -0.59% | 47.64 | 47.80 | 46.81 |
Pfizer Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Friday, April 28, 2023 | ||
| Time (UTC) 13:00 | Country US
| Event Pfizer Inc Annual Shareholders Meeting Pfizer Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, May 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2023 Pfizer Inc Earnings Release Q1 2023 Pfizer Inc Earnings ReleaseForecast -Previous - |
| Thursday, May 18, 2023 | ||
| Time (UTC) 10:59 | Country IN
| Event Q4 2023 Pfizer Ltd Earnings Release Q4 2023 Pfizer Ltd Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Ienākumi | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Cost of Revenue, Total | 11925 | 10838 | 8872 | 8043 | 8405 | 30688 |
| Bruto Peļņa | 40899 | 41708 | 31953 | 33129 | 33246 | 50600 |
| Kopējie Darbības Izdevumi | 43820 | 39557 | 36763 | 28841 | 33839 | 57636 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 14837 | 14784 | 12419 | 12485 | 11402 | 12256 |
| Pētniecība un Attīstība | 7872 | 7657 | 7713 | 7731 | 9340 | 11582 |
| Depreciation / Amortization | 4056 | 4758 | 4736 | 4462 | 3348 | 3700 |
| Neparedzēti Izdevumi (Ienākumi) | 6058 | 2594 | 4675 | -2914 | 2619 | 3897 |
| Other Operating Expenses, Total | -928 | -1074 | -1652 | -966 | -1275 | -4487 |
| Darbības Izdevumi | 9004 | 12989 | 4062 | 12331 | 7812 | 23652 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -824 | -972 | -538 | -877 | -538 | 560 |
| Gain (Loss) on Sale of Assets | 171 | 288 | 71 | 32 | -237 | 99 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 8351 | 12305 | 3594 | 11485 | 7036 | 24311 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 7228 | 11954 | 3264 | 10545 | 6666 | 22459 |
| Mazākuma Interese | -31 | -47 | -36 | -29 | -36 | -45 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 7197 | 11907 | 3228 | 10516 | 6630 | 22414 |
| Ārkārtas Posteņi Kopā | 17 | 9402 | 7924 | 5757 | 2529 | -434 |
| Neto Ienākumi | 7214 | 21309 | 11152 | 16273 | 9159 | 21980 |
| Total Adjustments to Net Income | 0 | -2 | 0 | -1 | 0 | -1 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 7197 | 11905 | 3228 | 10515 | 6630 | 22413 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Atšķaidītie Neto Ienākumi | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Atšķaidītie Ienākumi par Akcijām | 6159 | 6058 | 5977 | 5675 | 5632 | 5708 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 1.16853 | 1.96517 | 0.54007 | 1.85286 | 1.1772 | 3.92659 |
| Dividends per Share - Common Stock Primary Issue | 1.2 | 1.28 | 1.36 | 1.44 | 1.52 | 1.56 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 2.10748 | 2.31727 | 1.04885 | 1.22837 | 1.45366 | 4.09303 |
| Citi, Neto | -1 | -1 | -1 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 14516 | 18977 | 24094 | 23635 | 25661 |
| Ienākumi | 14516 | 18977 | 24094 | 23635 | 25661 |
| Cost of Revenue, Total | 4187 | 6986 | 9925 | 9611 | 10010 |
| Bruto Peļņa | 10329 | 11991 | 14169 | 14024 | 15651 |
| Kopējie Darbības Izdevumi | 8989 | 13063 | 16447 | 19059 | 15788 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 2901 | 2794 | 2733 | 4069 | 2691 |
| Pētniecība un Attīstība | 2010 | 2270 | 2738 | 4565 | 2655 |
| Depreciation / Amortization | 858 | 931 | 981 | 916 | 835 |
| Neparedzēti Izdevumi (Ienākumi) | -25 | 754 | 1613 | 1283 | 122 |
| Other Operating Expenses, Total | -942 | -672 | -1543 | -1385 | -525 |
| Darbības Izdevumi | 5527 | 5914 | 7647 | 4576 | 9873 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 127 | 637 | 190 | -394 | -823 |
| Gain (Loss) on Sale of Assets | 39 | 58 | 1 | 0 | 1 |
| Citi, Neto | -1 | -2 | 1 | -1 | |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 5692 | 6609 | 7836 | 4183 | 9050 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 4884 | 5566 | 8167 | 3849 | 7878 |
| Mazākuma Interese | -9 | -26 | -12 | 2 | -6 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 4875 | 5540 | 8155 | 3851 | 7872 |
| Ārkārtas Posteņi Kopā | 1 | 24 | -9 | -458 | -9 |
| Neto Ienākumi | 4876 | 5564 | 8146 | 3393 | 7863 |
| Total Adjustments to Net Income | 1 | -1 | 1 | ||
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 4876 | 5539 | 8155 | 3851 | 7873 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 4877 | 5563 | 8146 | 3393 | 7864 |
| Atšķaidītie Neto Ienākumi | 4877 | 5563 | 8146 | 3393 | 7864 |
| Atšķaidītie Ienākumi par Akcijām | 5662 | 5678 | 5725 | 5768 | 5758 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.86118 | 0.97552 | 1.42445 | 0.66765 | 1.36732 |
| Dividends per Share - Common Stock Primary Issue | 0.39 | 0.39 | 0.39 | 0.39 | 0.4 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.82179 | 1.06851 | 1.40629 | 0.74896 | 1.31052 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 38949 | 41141 | 49926 | 32803 | 35067 | 59693 |
| Nauda un Īstermiņa Ieguldījumi | 17850 | 19992 | 18833 | 9646 | 12221 | 31069 |
| Nauda un Ekvivalenti | 2595 | 1342 | 1139 | 1121 | 1784 | 1944 |
| Īstermiņa Ieguldījumi | 15255 | 18650 | 17694 | 8525 | 10437 | 29125 |
| Debitoru Parādu Kopsumma, Neto | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Accounts Receivable - Trade, Net | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Total Inventory | 6783 | 7578 | 7508 | 7068 | 8046 | 9059 |
| Other Current Assets, Total | 6091 | 5350 | 15560 | 9317 | 6870 | 8086 |
| Total Assets | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Property/Plant/Equipment, Total - Net | 13318 | 13865 | 13385 | 14258 | 15293 | 17721 |
| Property/Plant/Equipment, Total - Gross | 28125 | 30037 | 29977 | 29248 | 30104 | 32794 |
| Accumulated Depreciation, Total | -14807 | -16172 | -16591 | -14990 | -14812 | -15074 |
| Goodwill, Net | 54449 | 55952 | 53411 | 48202 | 49577 | 49208 |
| Intangibles, Net | 52648 | 48741 | 35211 | 33936 | 28471 | 25146 |
| Long Term Investments | 7116 | 7015 | 2767 | 20147 | 20262 | 21526 |
| Other Long Term Assets, Total | 5135 | 5083 | 4722 | 18248 | 5559 | 8182 |
| Total Current Liabilities | 31115 | 30427 | 31858 | 37304 | 25920 | 42671 |
| Accounts Payable | 4536 | 4656 | 4674 | 3887 | 4309 | 5578 |
| Accrued Expenses | 2487 | 2196 | 2397 | 2659 | 3379 | 3781 |
| Notes Payable/Short Term Debt | 6463 | 6407 | 4055 | 14733 | 701 | 605 |
| Current Port. of LT Debt/Capital Leases | 4225 | 3546 | 4776 | 1462 | 2002 | 1636 |
| Other Current Liabilities, Total | 13404 | 13622 | 15956 | 14563 | 15529 | 31071 |
| Total Liabilities | 112071 | 100489 | 96015 | 104450 | 90991 | 104276 |
| Total Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Deferred Income Tax | 30753 | 3900 | 3700 | 5652 | 4063 | 349 |
| Minority Interest | 296 | 348 | 351 | 303 | 235 | 262 |
| Other Liabilities, Total | 18509 | 32276 | 27197 | 25236 | 23640 | 24799 |
| Total Equity | 59544 | 71308 | 63407 | 63144 | 63238 | 77200 |
| Preferred Stock - Non Redeemable, Net | 24 | 21 | 19 | 17 | 0 | |
| Common Stock | 461 | 464 | 467 | 468 | 470 | 473 |
| Additional Paid-In Capital | 82685 | 84278 | 86253 | 87428 | 88674 | 90591 |
| Retained Earnings (Accumulated Deficit) | 71774 | 85291 | 89554 | 97670 | 96770 | 103394 |
| Treasury Stock - Common | -84364 | -89425 | -101610 | -110801 | -110988 | -111361 |
| Unrealized Gain (Loss) | -131 | 401 | -68 | -35 | 116 | -220 |
| Other Equity, Total | -10905 | -9722 | -11208 | -11603 | -11804 | -5677 |
| Total Liabilities & Shareholders’ Equity | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Total Common Shares Outstanding | 6070 | 5979 | 5717 | 5534 | 5567 | 5620 |
| Total Preferred Shares Outstanding | 0.0006 | 0.00052 | 0.00048 | 0.00043 | 0 | 0 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 39533 | 48814 | 57900 | 59693 | 54420 |
| Nauda un Īstermiņa Ieguldījumi | 13667 | 21700 | 29696 | 31069 | 23897 |
| Nauda un Ekvivalenti | 1768 | 2372 | 1966 | 1944 | 2470 |
| Īstermiņa Ieguldījumi | 11899 | 19328 | 27730 | 29125 | 21427 |
| Debitoru Parādu Kopsumma, Neto | 9864 | 10587 | 11897 | 11479 | 13225 |
| Accounts Receivable - Trade, Net | 9864 | 10587 | 11897 | 11479 | 13225 |
| Total Inventory | 8493 | 8948 | 8640 | 9059 | 9979 |
| Other Current Assets, Total | 7509 | 7579 | 7667 | 8086 | 7319 |
| Total Assets | 158818 | 169920 | 179188 | 181476 | 183841 |
| Property/Plant/Equipment, Total - Net | 14011 | 14224 | 14436 | 14882 | 15109 |
| Property/Plant/Equipment, Total - Gross | 29116 | 29552 | 29839 | 29955 | 30467 |
| Accumulated Depreciation, Total | -15105 | -15328 | -15403 | -15074 | -15358 |
| Goodwill, Net | 49791 | 49867 | 49489 | 49208 | 50211 |
| Intangibles, Net | 27974 | 27323 | 26306 | 25146 | 29816 |
| Long Term Investments | 20228 | 20942 | 21597 | 21526 | 20737 |
| Other Long Term Assets, Total | 7281 | 8750 | 9460 | 11021 | 13548 |
| Total Current Liabilities | 26652 | 35664 | 41803 | 42671 | 39268 |
| Accounts Payable | 4064 | 4327 | 4698 | 5578 | 5506 |
| Accrued Expenses | 1985 | 2015 | 2571 | 3332 | 2249 |
| Notes Payable/Short Term Debt | 676 | 201 | 966 | 605 | 385 |
| Current Port. of LT Debt/Capital Leases | 3676 | 3687 | 2663 | 1636 | 260 |
| Other Current Liabilities, Total | 16251 | 25434 | 30905 | 31520 | 30868 |
| Total Liabilities | 90198 | 99878 | 103496 | 104276 | 101417 |
| Total Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Deferred Income Tax | 4355 | 4161 | 328 | 349 | 655 |
| Minority Interest | 245 | 273 | 275 | 262 | 261 |
| Other Liabilities, Total | 23599 | 24426 | 24840 | 24799 | 25577 |
| Total Equity | 68620 | 70042 | 75692 | 77200 | 82424 |
| Common Stock | 472 | 472 | 473 | 473 | 476 |
| Additional Paid-In Capital | 89002 | 89336 | 89973 | 90591 | 90844 |
| Retained Earnings (Accumulated Deficit) | 95158 | 96346 | 102252 | 103394 | 111193 |
| Treasury Stock - Common | -111349 | -111356 | -111359 | -111361 | -113931 |
| Unrealized Gain (Loss) | -26 | 79 | -146 | -220 | -133 |
| Other Equity, Total | -4637 | -4835 | -5501 | -5677 | -6025 |
| Total Liabilities & Shareholders’ Equity | 158818 | 169920 | 179188 | 181476 | 183841 |
| Total Common Shares Outstanding | 5594 | 5599 | 5611 | 5620 | 5591 |
| Total Preferred Shares Outstanding | 0 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 7246 | 21355 | 11188 | 16302 | 9652 | 22025 |
| Nauda no Darbības | 16193 | 16802 | 15827 | 12587 | 14403 | 32580 |
| Nauda no Darbības | 5757 | 6269 | 6384 | 6010 | 4777 | 5191 |
| Deferred Taxes | -700 | -2410 | -2205 | 614 | -1468 | -4293 |
| Bezskaidras Naudas Preces | 3791 | -9748 | 1387 | -6307 | 1717 | -3147 |
| Cash Taxes Paid | 2521 | 2489 | 3655 | 3664 | 3153 | 7427 |
| Samaksātie Procenti Naudā | 1451 | 1518 | 1311 | 1587 | 1641 | 1467 |
| Izmaiņas Apgrozāmajā Kapitālā | 99 | 1336 | -927 | -4032 | -275 | 12804 |
| Nauda no Ieguldījumu Darbībām | -7791 | -4740 | 4525 | -3945 | -4271 | -22546 |
| Kapitālie Izdevumi | -1999 | -2217 | -2196 | -2594 | -2791 | -2711 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -5792 | -2523 | 6721 | -1351 | -1480 | -19835 |
| Nauda no Darbībām ar Finansēšanu | -9228 | -13350 | -20441 | -8485 | -9649 | -9816 |
| Naudas Plūsma Finansēšanas Posteņos | -536 | -612 | -589 | -735 | 11121 | 16 |
| Total Cash Dividends Paid | -7317 | -7659 | -7978 | -8043 | -8440 | -8729 |
| Akciju Izsniegšana (Atkāpšanās), Neto | -3981 | -4138 | -10939 | -8471 | 425 | 0 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 2606 | -941 | -935 | 8764 | -12755 | -1103 |
| Ārvalstu Valūtas Ietekme | -215 | 53 | -116 | -32 | -8 | -59 |
| Neto Izmaiņas Naudā | -1041 | -1235 | -205 | 125 | 475 | 159 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 4886 | 10475 | 18633 | 22025 | 7870 |
| Cash From Operating Activities | 4539 | 15836 | 26666 | 32580 | 6541 |
| Cash From Operating Activities | 1226 | 2554 | 3914 | 5191 | 1187 |
| Deferred Taxes | 199 | -3702 | -4293 | -2321 | |
| Non-Cash Items | -446 | -1590 | -2997 | -3147 | 537 |
| Cash Taxes Paid | 394 | 2188 | 2943 | 7427 | 354 |
| Cash Interest Paid | 445 | 798 | 1205 | 1467 | 453 |
| Changes in Working Capital | -1326 | 4397 | 10818 | 12804 | -732 |
| Cash From Investing Activities | -1747 | -9884 | -19960 | -22546 | 567 |
| Capital Expenditures | -554 | -1094 | -1718 | -2711 | -643 |
| Other Investing Cash Flow Items, Total | -1193 | -8790 | -18242 | -19835 | 1210 |
| Cash From Financing Activities | -2807 | -5364 | -6465 | -9816 | -6578 |
| Financing Cash Flow Items | -610 | -510 | -185 | 16 | -500 |
| Total Cash Dividends Paid | -2172 | -4355 | -6540 | -8729 | -2249 |
| Issuance (Retirement) of Debt, Net | -25 | -499 | 260 | -1103 | -1829 |
| Foreign Exchange Effects | 0 | 5 | -32 | -59 | -1 |
| Net Change in Cash | -15 | 593 | 209 | 159 | 529 |
| Issuance (Retirement) of Stock, Net | 0 | -2000 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7471 | 491001204 | 5107541 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1238 | 287612741 | 395713 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0984 | 286187374 | 1836743 | 2022-09-30 | LOW |
| Capital World Investors | Investment Advisor | 4.4332 | 248850529 | -1276218 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.7567 | 210874152 | -8297495 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9675 | 110442140 | 1859302 | 2022-09-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2492 | 70123906 | 6001894 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0112 | 56763604 | 200794 | 2021-12-31 | LOW |
| Capital International Investors | Investment Advisor | 0.9856 | 55323878 | 5892896 | 2022-09-30 | LOW |
| State Farm Insurance Companies | Insurance Company | 0.9543 | 53568997 | 0 | 2022-09-30 | LOW |
| BofA Global Research (US) | Research Firm | 0.803 | 45074753 | -582392 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7631 | 42832953 | -453753 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7449 | 41814509 | -977163 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.7363 | 41330356 | 393541 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7347 | 41242414 | 1009399 | 2022-09-30 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.7287 | 40906577 | -874608 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6492 | 36441408 | 1403401 | 2022-09-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.632 | 35478928 | -2969100 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.5195 | 29162770 | -5775440 | 2022-09-30 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.5151 | 28915413 | -87396 | 2022-09-30 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +500000+
Tirgotāji
93000+
Ikmēneša aktīvie klienti
$57000000+
Ikmēneša ieguldījumu apjoms
$31000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Pfizer Company profile
Par Pfizer Inc
Pfizer Inc. ("Pfizer") ir globāls biofarmācijas uzņēmums, kas darbojas pētniecības jomā. Uzņēmums nodarbojas ar biofarmaceitisko produktu atklāšanu, izstrādi, ražošanu, tirdzniecību, pārdošanu un izplatīšanu. Tā globālais portfelis ietver zāles un vakcīnas. Uzņēmums piedāvā terapeitiskus kandidātus gastroenteroloģijā, dermatoloģijā un kardioloģijā, tostarp etrasimodu, perorālu selektīvu sfingozīn-1-fosfāta (S1P) receptora modulatoru, kas tiek izstrādāts dažādu imūniekaisuma slimību, tostarp čūlainā kolīta, Krona slimības, atopiskā dermatīta, eozinofīlā ezofagīta un alopēcija areata, ārstēšanai. Uzņēmums darbojas dažādos tirgos, lai attīstītu labsajūtu, profilaksi, ārstēšanu un ārstēšanu. Tā sadarbojas ar veselības aprūpes sniedzējiem, valdībām un vietējām kopienām, lai atbalstītu un nodrošinātu veselības aprūpes pieejamību. Uzņēmuma zāles un vakcīnas nodrošina vērtību veselības aprūpes sniedzējiem un pacientiem, ārstējot slimības, uzlabojot veselību un labsajūtu.
| Industry: | Pharmaceuticals (NEC) |
235 E 42nd St
NEW YORK
NEW YORK 10017
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com